

A cluster-randomized trial of client and provider directed financial interventions to align incentives with appropriate case management in private medicine retailers: results of the TESTsmART Trial in Lagos, Nigeria

Short title: Improving malaria case management in private medicine retailers

Authors: T. Visser^{1*}, J. Laktabai², E. Kimachas³, J. Kipkoech³, D. Menya⁴, D. Arthur⁵, Y. Zhou⁶, T. Chepkwony³, L. Abel⁴, E. Robie⁷, M. Amunga³, G. Ambani³, P. Uhomoibhi⁸, N. Ogbulafor⁸, B. Oshinowo⁹, O. Ogunsola¹⁰, M. Woldeghebriel¹¹, E. Garber¹², T. Olaleye¹², N. Eze¹², L. Nwidae¹², P. Mudabai¹², J.A. Gallis⁵, C. Fashanu¹², I. Saran¹³, A. Woolsey¹, E.L. Turner⁵, W. Prudhomme O'Meara¹⁴

¹ Clinton Health Access Initiative (CHAI), Boston, Massachusetts, United States of America

² Moi University School of Medicine, College of Health Sciences, Moi University, Eldoret, Kenya

³ Academic Model Providing Access to Health Care, Eldoret, Kenya

⁴ Moi University School of Public Health, College of Health Sciences, Moi University, Kenya

⁵ Department of Biostatistics & Bioinformatics and Duke Global Health Institute, Duke University, Durham, North Carolina, United States of America

⁶ Department of Biostatistics, University of Washington, Seattle, Washington, United States of America

⁷ Duke Global Health Institute, Duke University, Durham, North Carolina, United States of America

⁸ National Malaria Elimination Program, Federal Ministry of Health & Social Welfare, Abuja, Nigeria

⁹ Lagos State Malaria Elimination Program, Lagos State Ministry of Health, Lagos, Nigeria

¹⁰ Simon Business School, University of Rochester, Rochester, New York, United States of America

¹¹ Clinton Health Access Initiative (CHAI), Kampala, Uganda

¹² Clinton Health Access Initiative (CHAI), Abuja, Nigeria

¹³ School of Social Work, Boston College, Massachusetts, United States of America

¹⁴ Duke Global Health Institute and Moi University School of Public Health, College of Health Science

* Corresponding author: tvisser@clintonhealthaccess.org

40 **Abstract**

41 Malaria remains a major health priority in Nigeria. Among children with fever who seek care, less than a
42 quarter gets tested for malaria, leading to inappropriate use of the recommended treatment for
43 malaria; Artemether Combination Therapies (ACT). Here we test an innovative strategy to target ACT
44 subsidies to clients seeking care in Nigeria's private retail health sector who have a confirmed malaria
45 diagnosis. We supported point-of-care malaria testing (mRDTs) in 48 Private Medicine Retailers (PMRs)
46 in the city of Lagos, Nigeria and randomized them to two study arms; a control arm offering subsidized
47 mRDT testing for USD \$0.66, and an intervention arm where, in addition to access to subsidized testing
48 as in the control arm, clients who received a positive mRDT at the PMR were eligible for a free (fully
49 subsidized) first-line ACT and PMRs received USD \$0.2 for every mRDT performed. Our primary outcome
50 was the proportion of ACTs dispensed to individuals with a positive diagnostic test. Secondary outcomes
51 included proportion of clients who were tested at the PMR and adherence to diagnostic test results.
52 Overall, 23% of clients chose to test at the PMR. Test results seemed to inform treatment decisions and
53 resulted in enhanced targeting of ACTs to confirmed malaria cases with only 26% of test-negative clients
54 purchasing an ACT compared to 58% of untested clients. However, the intervention did not offer further
55 improvements, compared to the control arm, in testing rates or dispensing of ACTs to test-positive
56 clients. We found that ACT subsidies were not passed on to clients testing positive in the intervention
57 arm. We conclude that RDTs could reduce ACT overconsumption in Nigeria's private retail health sector,
58 but PMR-oriented incentive structures are difficult to implement and may need to be complemented
59 with interventions targeting clients of PMRs to increase test uptake and adherence.

60 Clinical Trials Registration Number: NCT04428307

61

62

63

64 **Introduction**

65 Malaria remains an urgent health priority in Nigeria where it is a leading cause of mortality. Globally,
66 Nigeria accounts for 27% of all malaria cases, exceeding 66 million per year [1]. Reported cases, which
67 are already the highest in the world, are on the rise, suggesting that beyond an expansion of malaria
68 testing and improved surveillance, the malaria burden might be getting worse [2]. Recent survey results
69 show that among children under 5 who had a fever in the two weeks before the survey, only 24% had
70 blood taken from a finger or heel for malaria testing [3]. Private health providers including private
71 medicine retailers (PMRs) such as Patent and Proprietary Medicine Vendors (PPMVs) and Community
72 Pharmacies play an important role in providing basic health services in Nigeria, including management of
73 suspected malaria cases. PMRs are widespread across Nigeria and are often the first point of care for
74 febrile patients. Household survey data suggests up to 60% of febrile children first seek care in PMRs [3].
75 Compliance with national malaria treatment guidelines is generally considered poor in these outlets
76 [4,5,6]. Few clients receive a confirmatory malaria diagnosis prior to treatment, with PMRs and their
77 clients often forgoing the test or taking antimalarials even when the test result is negative [7].

78

79 Here we report the results of the *Malaria diagnostic testing and conditional subsidies to target ACTs in*
80 *the retail sector* (TESTsmART) trial in Nigeria, a two-arm cluster randomized trial designed to test the
81 effect of conditional ACT subsidies and modest provider incentives on appropriate use of ACT and
82 malaria Rapid Diagnostic Test (mRDT) in the retail sector. The study was conducted in the urban center
83 of Lagos State, located in South-Western region of Nigeria, where 2.6 million malaria cases (3.8% of
84 Nigeria's total cases) were recorded in 2021 [2].

85

86

87 **Methods**

88 *Overall study design*

89 This study was a two-arm cluster randomized controlled trial focused on malaria diagnostic testing and
90 conditional ACT subsidies with the goal of evaluating the effect of provider-directed and client-directed
91 interventions on improving the management of suspected malarial fevers that receive care in the retail
92 sector. The study site was the urban center of Lagos, Lagos State, Nigeria. We enrolled 48 PPMV outlets
93 (clusters) in the study. Inclusion criteria for PPMV outlets were: (i) Routinely stock and sell ACTs; (ii)
94 Willing to acquire mRDTs and use in diagnosing malaria for clients; (iii) Willing to use a phone/app to
95 collect/report data and receive incentives to conduct mRDTs; (iv) Willing to allow a data collector to
96 conduct patient exit interviews for several days each month at the outlet; (v) Up-to-date
97 license/registration. Exclusion criteria for outlets were (i) Having challenges with network connectivity at
98 the outlet; (ii) Participating in other studies/NGO projects and (iii) Having any agreements with
99 drug/diagnostic marketers.

100

101 The diagnosis and treatment choices made during each transaction were captured using a mobile phone
102 reporting app. This app was designed specifically for the purposes of the study. Each outlet was
103 provided a mobile phone with the app and monthly data bundles to use the app. Outlet attendants were
104 asked to use the app for each client with suspected malaria. The app included a few questions on the
105 client's symptoms and if an RDT was conducted, it prompted the user to take and upload a picture of the
106 RDT result.

107

108 Study outcomes were collected through exit interviews with clients, who sought care for febrile illness at
109 any of the enrolled PPMVs. Inclusion criteria for clients to be eligible for the exit interview were: (i)
110 Participants had a fever or history of fever in the last 48 hours or malaria-like illness; (ii) Individuals with
111 malaria-like illness was present at recruitment and (iii) Older than one year of age. Exclusion criteria
112 were (i) Individuals with any signs of severe illness requiring immediate referral; (ii) Individuals who had
113 taken an antimalarial in the last seven days, including for the current illness; (iii) Individuals that were
114 under 18 years of age without a parent or legal guardian present and (iv) Individuals that were unable to
115 consent. Written informed consent was obtained from the parent/guardian of each participant under 18
116 years of age.

117
118 This study is linked to a similar cluster randomized controlled trial in the contrasting rural study site of
119 the region around Webuye in western Kenya. These results are pending publication elsewhere [8]. Full
120 details of the study design were previously reported in Woolsey *et al* [9, 10].

121

122 *Study area*

123 The study was conducted in Lagos, Nigeria, a large urban metropolis in southern Nigeria where malaria
124 prevalence is around 3% and point-of-care rapid testing through mRDTs has been permitted in PPMVs
125 since 2011 [11].

126

127 *Intervention*

128 The two intervention arms considered for evaluation were:

- 129 1. Control intervention: mRDTs were made available at a wholesale price to the participating PPMV
130 (120 Naira or approximately USD \$0.31 per test), as per the USD/Naira exchange rate at the onset of
131 the implementation phase in March 2022. Outlet owner/attendants were trained to use the mobile

132 reporting app. mRDTs were offered to clients at a pre-determined price (250 Naira per test or
133 approximately USD \$0.66).

134 2. Provider-directed and client-directed intervention: in addition to the interventions implemented in
135 the control outlets, the retail outlet owner received a small incentive (250 Naira or approximately
136 USD \$0.66) for each mRDT they conducted and reported using the mobile app. Clients visiting
137 outlets in this arm received a free ACT (cost equivalent to 850 Naira or approximately USD \$2.12 for
138 adults and 650 Naira or approximately USD \$1.62 for children) if they purchased an mRDT and
139 received a positive test result (conditional subsidy).

140
141 Originally, the study was planned as a four-arm study, splitting provider directed and client directed
142 interventions in separate arms in addition to a control and the combined intervention arm, but due to
143 substantial differences between the initial study assumptions and actual observations during the first
144 seven months of data collection, the study was re-started in February 2022 with two arms rather than
145 four to address the anticipated loss of power. The recruitment period for the 2-arm design started
146 March 1st, 2022, and ran until February 28th, 2023. For a detailed explanation of the change from the
147 originally planned 4-arm design to a 2-arm design please refer to Woolsey *et al* [10].

148

149 *Study outcome measures*

150 The primary outcome was ACT consumption by parasitologically confirmed malaria cases, defined as the
151 proportion of ACTs that were dispensed to malaria test-positive clients, including those who were tested
152 at the outlet and those who came with documentation of a positive test result (either microscopy or
153 mRDT) from another provider. There were four secondary outcomes, all binary:

- 154 1. Use of malaria rapid diagnostic test: Proportion of suspected malaria cases that received a
155 malaria test, where a suspected case was any client who was tested with an mRDT or was
156 untested but purchased an antimalarial (AM) of any type.
- 157 2. Adherence to mRDT result: Proportion of malaria tested clients whose treatment adhered to
158 test results (tested positive with mRDT and purchased ACT or tested negative with mRDT and
159 did not purchase AM).
- 160 3. Appropriate case management: Proportion of suspected malaria cases (defined as above in 1.)
161 that were managed appropriately (same numerator as for “Adherence to mRDT result”
162 outcome, but with all suspected malaria cases as denominator).
- 163 4. ACT use among the untested: Proportion of untested clients who purchased ACT.

164

165 *Power calculations*

166 All power calculations were based on pairwise comparison of two proportions using a formula for
167 comparing two proportions under a cluster-randomized trial design [12]. We estimated the intra-class
168 correlation coefficient (ICC) for the primary outcome to be 0.037. In order to account for varying cluster
169 sizes, we modified the Hayes and Moulton formula for comparing two proportions by replacing the
170 cluster size (m) with $m/(1 + CV^2)$, where CV is the coefficient of variation of cluster sizes and was
171 estimated to be 0.72 (13). Based on these assumptions, we expected to achieve greater than 90% power
172 to detect a difference of 12 percentage points in the primary outcome for our comparison of the
173 intervention arm to the control arm.

174

175 *Randomization and recruitment*

176 For the purposes of the two-arm trial, 48 retail PPMVs were equally randomly assigned to each of the
177 two arms by the study statistician. Randomization was constrained to stratify by three geographic

178 regions of Lagos, and additionally constrained such that any outlets in close proximity to one another
179 (<0.5km) were assigned to the same arm to avoid potential contamination of treatment effects. For
180 additional details about the randomization procedures before and after the design change from four
181 arms to two arms, see the analysis plan in the supplement.

182

183 *Study implementation*

184 Enrolled PPMV outlets were trained on Nigeria's national malaria case management guidelines, correct
185 mRDT procedures, and the use of the study mobile app to record client encounter data and take photos
186 of mRDT results. Outlets were also equipped with arm specific leaflets and banners placed outside of the
187 outlet, encouraging customers to test for malaria in the outlet. During a 3-month pilot period, the
188 outlets started collecting data on the mobile app and performing mRDTs. Outlets were monitored
189 closely to make sure testing and app issues were resolved during the pilot period. After the pilot period,
190 outlets were trained in arm-specific groups on the intervention guidelines for client and provider-
191 directed incentives, as applicable. Outlets were also informed of the exit interview process being
192 conducted outside of their outlet, independently of the client-outlet interaction.

193

194 Throughout the 12-month intervention period, the study team conducted regular supervision visits to
195 ensure good adherence to testing and safety procedures, troubleshoot challenges with the mobile app
196 and provide onsite mentorship to all outlets. Outlets that were running low on RDTs were urged to
197 contact the supplier contracted to supply mRDTs for deliveries directly to the outlet. Any abnormal
198 mRDT photographs observed submitted via the app were passed along to supervisors to discuss with the
199 outlets.

200

201 Subsidies and incentives were paid weekly to bank accounts of the owners of the intervention outlets.
202 Outlets allocated to the intervention arm agreed to give free Artemether Lumefantrine (AL) to test-
203 positive clients for which they were reimbursed by the study (650 Naira for children 9 years and below
204 and 850 Naira for clients 10 years and above, correlating with the price of the different dosages for each
205 age range). Outlets also received a small payment for administering mRDTs to clients (100 Naira),
206 regardless of test result. Payments were calculated based on photographs of mRDTs uploaded to the
207 study app. Outlets were paid for the total number of tests conducted, and for the total number of
208 positive mRDTs, as observed through the study app. For this study, reimbursable ACTs were restricted to
209 authorized AL brands (i.e., Registered by the national regulatory authority in Nigeria; the National
210 Agency for Food and Drug Administration and Control (NAFDAC) and approved by World Health
211 Organization Pre-Qualification Program) in a tablet formulation we found to be widely available among
212 the participating outlets (Lonart/ CoArtem/ Lumartem).

213

214 *Data collection*

215 Interviews were conducted with clients departing from participating PPMVs (study clusters) on random
216 days of the week. All clients exiting the PPMV that day were eligible to be screened. Exit interviewers
217 were instructed to make no pre-judgements about clients but rather approach each client exiting the
218 outlet. Data for participant exit interviews was collected electronically via tablet. The primary tool for
219 developing the data collection forms was REDCap hosted at Duke University.

220

221 *Statistical analysis*

222 Characteristics of enrolled participants were summarized by study arm using means and standard
223 deviations for continuous variables and counts and percentages for categorical variables. We analyzed
224 all client-level self-reported primary and secondary outcomes using a modified Poisson approach with

225 robust standard errors, with log link to estimate risk ratios (RRs) and identity link to estimate risk
226 differences (RDs) [14,15]. The modified Poisson approach was implemented within the generalized
227 estimating equations (GEE) framework to account for clustering of outcomes by outlet and utilizing an
228 independence working correlation to avoid bias in estimating the treatment effect [16]. Moreover,
229 because there were fewer than 50 clusters, the robust standard errors were further adjusted for
230 potential “small-sample” bias using the Kauermann-Carroll correction [17, 18]. All models included fixed
231 effects for the intervention arm indicators, the stratification variable (county), and time (in months,
232 including linear, quadratic, and cubic terms) to account for potential imbalanced recruitment over the
233 12-month follow-up period (minimally adjusted models). Model-based ICC for the primary outcome was
234 calculated using this minimally adjusted model. We also present fully adjusted models which include the
235 following potential confounder variables: client gender, client age, level of schooling, and wealth index.
236
237 We intended to estimate correlation parameters using the matrix-adjusted estimating equation (MAEE)
238 approach [19], but this approach did not converge. Therefore, we reverted to the GEE approach with
239 method of moments estimation of correlation parameters. Inference for parameters of the mean model
240 was based on the t-statistic with degrees of freedom $I - p$, where I was the number of clusters (PPMV
241 outlets) and p was the number of parameters in the mean model (specifically of the cluster-level
242 covariates, including the intercept, treatment indicator, and time). All analyses were based on the
243 intention-to-treat principle. Since we did not have longitudinal follow-up of clients, we did not need to
244 account for missing data due to attrition of clients. Clients missing specific data elements were excluded
245 from models requiring those variables as indicated in the tables. Overall, there was relatively little
246 missing data for variables included in the minimally adjusted models. For the fully adjusted models,
247 approximately 15% of participants were missing data required for the construction of the wealth score,
248 and 10% were missing information on their education level.

249

250

251

252 *Ethical considerations and trial registration:*

253 The study was reviewed and approved by CHAI's Scientific and Ethical Review Committee (SERC) on

254 October 22nd 2019; Duke University Institutional Review Board (Pro00104256) and the Health Research

255 and Ethics Committee Secretariat (HREC) at the Lagos State University Teaching Hospital (LASUTH)

256 (LREC/06/10/1304) in Lagos, Nigeria. The study is registered in ClinicalTrials.gov (NCT04428307) and the

257 protocol and revisions to the original design were published in advance [9,10].

258

259 **Results**

260 *Population analysis*

261 Between early March 2022 and late February 2023, data were collected from exiting clients on 251

262 outlet-days of observation. Out of 12,947 clients screened, 2,441 or 19% were eligible (i.e., met the

263 inclusion criteria) and provided consent across the two arms. Most ineligible clients (8,608 or 82%)

264 indicated not having a fever or malaria-like illness; some (1,049 or 10%) ineligible clients indicated that

265 they visited the outlet for someone else with malaria-like symptoms that was not present. Of the 2,205

266 enrolled, consenting and eligible clients, 1,815 or 82% were adults who had malaria-like symptoms; 388

267 or 18%, were the caregiver of a sick child. The median age of the child was 5. Eligible clients showed an

268 even split in gender. Almost half (49% or 1,065) of respondents (adult client or caregiver of child client)

269 were between ages 26-39, and 17% or 367 respondents were between ages 18-25. Over the 12-month

270 collection period starting in early March 2022, 31% of exit interviews were collected between

271 September and November 2022, with the other interviews split evenly across the remaining three 3-
272 month periods (20-25%). Almost half of respondents (915 or 47%) achieved high school as the highest
273 level of education, 451 or 23% a university degree and 404 or 21% a vocational degree. We did not
274 observe any notable differences in respondent characteristics across arms (Fig 1, Table 1).

275

276 **Table 1: Characteristics of participants enrolled in TESTsmART by arm.**

277

Characteristic	Study Arm		
	Control	Intervention	Overall
Interviewees, N ¹	1,101	1,104	2,205
Respondent, n (%)			
Adult client	926 (84%)	889 (81%)	1,815 (82%)
Guardian of child client	175 (16%)	213 (19%)	388 (18%)
Missing	0	2	2
Adult clients, n	926	889	1,815

Characteristic	Study Arm		
	Control	Intervention	Overall
Age, n (%)			
18-25	178 (19%)	173 (19%)	351 (19%)
26-39	404 (44%)	414 (47%)	818 (45%)
40-59	307 (33%)	258 (29%)	565 (31%)
60-79	34 (3.7%)	40 (4.5%)	74 (4.1%)
80 and above	3 (0.3%)	3 (0.3%)	6 (0.3%)
Missing	0	1	1
Gender, n (%)			
Male	515 (56%)	440 (49%)	955 (53%)
Female	411 (44%)	449 (51%)	860 (47%)
Education level, n (%)			
None	42 (5.0%)	30 (3.8%)	72 (4.4%)
Primary	54 (6.4%)	31 (4.0%)	85 (5.2%)
Secondary	395 (47%)	347 (44%)	742 (46%)
University	166 (20%)	213 (27%)	379 (23%)
Polytechnic	181 (22%)	162 (21%)	343 (21%)
Missing	88	106	194
Child clients, n	175	213	388
Respondent for child			
Age, n (%)			
18-25	12 (6.9%)	4 (2.0%)	16 (4.2%)
26-39	102 (58%)	144 (70%)	246 (65%)
40-59	60 (34%)	54 (26%)	114 (30%)

Characteristic	Study Arm		
	Control	Intervention	Overall
60-79	1 (0.6%)	3 (1.5%)	4 (1.1%)
80 and above	0 (0%)	0 (0%)	0 (0%)
Missing	0	8	8
Gender, n (%)			
Male	39 (22%)	56 (26%)	95 (25%)
Female	136 (78%)	156 (74%)	292 (75%)
Missing	0	1	1
Education level, n (%)			
None	11 (6.7%)	6 (3.3%)	17 (4.9%)
Primary	16 (9.8%)	6 (3.3%)	22 (6.4%)
Secondary	77 (47%)	95 (53%)	172 (50%)
University	30 (18%)	42 (23%)	72 (21%)
Polytechnic	30 (18%)	31 (17%)	61 (18%)
Missing	11	33	44
Child client age			
Mean (SD)	6.5 (4.2)	6.1 (4.3)	6.3 (4.2)
Median [IQR]	5.5 [3.0, 10.0]	5.0 [2.5, 10.0]	5.0 [3.0, 10.0]
Range	1.0, 17.0	1.0, 17.0	1.0, 17.0
Missing	1	0	1
Child client gender, n (%)			
Male	78 (45%)	102 (48%)	180 (46%)
Female	97 (55%)	111 (52%)	208 (54%)
All clients, n	1,101	1,104	2,205

Study Arm			
Characteristic	Control	Intervention	Overall
Wealth index (quintile), n (%)			
0 to 20 th	245 (26%)	197 (21%)	442 (24%)
>20.0 to 40 th	166 (17%)	147 (16%)	313 (17%)
>40.0 to 60 th	253 (27%)	205 (22%)	458 (24%)
>60.0 to 80 th	153 (16%)	170 (18%)	323 (17%)
>80.0	137 (14%)	201 (22%)	338 (18%)
Missing	147	184	331
Time Period, n (%)			
Feb-May 2022	226 (21%)	207 (19%)	433 (20%)
Jun-Aug 2022	241 (22%)	307 (28%)	548 (25%)
Sep-Nov 2022	359 (33%)	334 (30%)	693 (31%)
Dec 2022-Feb 2023	275 (25%)	256 (23%)	531 (24%)
¹ Includes only interviewees who consented and met all inclusion criteria.			

278

279 *Outcomes*

280 We found no statistically significant impact of the intervention on the primary outcome of the
 281 proportion of ACTs sold to test-positive clients (Intervention: Control, Adj RR=0.85 [0.34 to 2.16]: 8.8%
 282 (49/558) in the control vs. 7.8% (49/626) in intervention arm). We also did not see any statistically
 283 significant impact on any of the other secondary outcomes (i.e., adherence to test result and
 284 appropriate case management); Intervention: Control, Adj RR=0.76 (0.36 to 1.62) and 0.67 (0.33 to
 285 1.33), respectively (Table 2).

286

287 **Table 2: Minimally adjusted and fully adjusted estimates of intervention effects for pre-specified**
 288 **study outcomes.**
 289

Arm	Proportion	Risk Ratio (95% CI)		Risk Difference (95% CI)	
		Minimally	Fully	Minimally	Fully
		Adjusted	Adjusted	Adjusted	Adjusted
Primary – ACTs sold to malaria test-positive clients					
Control	49/558 (8.8%)	—	—	—	—
Intervention	49/626 (7.8%)	0.85 (0.34, 2.16)	0.79 (0.27, 2.33)	-0.01 (-0.09, 0.07)	-0.02 (-0.10, 0.07)
Secondary 1 – Suspected malaria cases that receive a mRDT (testing uptake)					
Control	226/928 (24%)	—	—	—	—
Intervention	217/958 (23%)	0.92 (0.47, 1.78)	0.95 (0.50, 1.81)	-0.01 (-0.20, 0.18)	0.01 (-0.18, 0.20)
Secondary 2 – Malaria tested clients whose treatment adhered to test results					
Control	167/226 (74%)	—	—	—	—
Intervention	118/217 (54%)	0.76 (0.36, 1.62)	0.77 (0.36, 1.64)	-0.17 (-0.36, 0.01)	-0.17 (-0.37, 0.03)
Secondary 3 – Suspected malaria cases that are managed appropriately					
Control	167/928 (18%)	—	—	—	—
Intervention	118/958 (12%)	0.67 (0.33, 1.33)	0.66 (0.33, 1.31)	-0.05 (-0.19, 0.10)	-0.06 (-0.24, 0.11)
Secondary 4 – Untested clients taking ACT					
Control	462/836 (55%)	—	—	—	—
Intervention	498/827 (60%)	1.09 (0.62, 1.90)	1.02 (0.60, 1.74)	0.05 (-0.03, 0.12)	0.01 (-0.08, 0.09)

290

291 *Testing rates*

292 Prior to the study, testing in the retail outlets was rarely offered. A survey performed prior to the start
293 of the study found that only 12% (n=153) of outlets in the study area had mRDTs in stock during the
294 time of the survey. Overall, during the study, 23% (443/1,886) of suspected cases (any client who was
295 tested with an mRDT or was untested but purchased an antimalarial (AM) of any type) received an RDT
296 at the outlet. We found no statistically significant impact of the intervention on testing rates
297 (Intervention: Control, Adj RR=0.92 [0.47 to 1.78]; 23% (217/958) of suspected cases were tested in the
298 intervention arm compared to 24% (226/928) in the control arm). Clients sometimes arrived with a test
299 or prescription from a private laboratory or physician. In exit interviews, about 5% (94/1,886) of
300 suspected cases came to the outlet with a diagnosis from another facility or laboratory. Few of these
301 clients chose to retest (n=4). Of the clients that were tested in the outlet, 56% were female and 44%
302 male. Of the clients that were not tested, 47% were female and 53% male. Most tests were done in the
303 Sept-Nov period (37%), vs. 20-25% in the other three periods. No other discernable differences in
304 wealth, education or age were observed when comparing those who were and were not tested (Table
305 3, Table S1).

306

307 **Table 3: Testing and treatment decisions by arm.**

308

Characteristic	Study Arm		
	Control	Intervention	Overall
Interviewees, n ¹	1,101	1,104	2,205
Tested at outlet, n	226	217	443

<i>Proportion tested at outlet, n</i>	(21%)	(20%)	(20%)
Positive test at outlet, n	27	29	56
<i>Proportion with positive test</i>	(12%)	(13%)	(13%)
Took AL, n (%)	22 (81%)	21 (72%)	43 (77%)
Took ACT (not AL), n (%)	3 (11%)	0 (0%)	3 (5.4%)
Took other antimalarial, n (%)	1 (3.7%)	6 (21%)	7 (13%)
Negative test at outlet, n	191	184	375
<i>Proportion with negative test</i>	(85%)	(85%)	(85%)
Took AL, n (%)	31 (16%)	62 (34%)	93 (25%)
Took ACT (not AL), n (%)	3 (1.6%)	3 (1.6%)	6 (1.6%)
Took other antimalarial, n (%)	15 (7.9%)	22 (12%)	37 (9.9%)
Invalid or unknown test result at outlet, n	8	4	12
Not tested at outlet, n	874	883	1,757
<i>Proportion not tested at outlet</i>	(79%)	(80%)	(80%)
No test, n	836	827	1,663
Took AL, n (%)	391 (47%)	422 (51%)	813 (49%)
Took ACT (not AL), n (%)	71 (8.5%)	76 (9.2%)	147 (8.8%)
Took other antimalarial, n (%)	203 (24%)	192 (23%)	395 (24%)
Had positive test from elsewhere, n	38	55	93
Took AL, n (%)	27 (71%)	27 (49%)	54 (58%)
Took ACT (not AL), n (%)	4 (11%)	12 (22%)	16 (17%)
Took other antimalarial, n (%)	6 (16%)	11 (20%)	17 (18%)
Had negative test from elsewhere, n	0	1	1
Took AL, n (%)	0 (NA%)	1 (100%)	1 (100%)
Took ACT (not AL), n (%)	0 (NA%)	0 (0%)	0 (0%)
Took other antimalarial, n (%)	0 (NA%)	0 (0%)	0 (0%)

309 ¹Includes only interviewees who consented and met all inclusion criteria.

310

311 *ACT consumption and adherence*

312 Across the study arms, we observed that testing seemed to have improved targeting of ACT. Of those
313 testing positive, 82.1% (46/56) purchased an ACT, compared to 26.4% (99/375) of those testing
314 negative. Amongst untested clients, 57.7% (960/1663) purchased an ACT. Overall, female clients had
315 higher adherence to negative test results (i.e., tested negative with mRDT and not purchased any anti-
316 malarial) than male clients (69% (146/213) vs. 57% (93/162)); male clients, in contrast, had higher
317 adherence to positive results. (i.e., tested positive with mRDT and purchased ACT) 88% (23/26) vs. 77%
318 (23/30). Of the seven women not purchasing an ACT (7/30), five purchased other antimalarials (Table 3,
319 Table S2).

320

321 *Understanding the intervention*

322 We found significant heterogeneity among participating outlets in RDT uptake. To understand the
323 variability, we examined differences in testing and treatment at the cluster level. We found a handful of
324 outlets were responsible for the vast majority of testing, with five outlets (out of 48) accounting for 41%
325 of mRDTs administered. Testing rates ranged from as low as 0% of suspected cases to more than 85%.
326 Although integration of testing into their business practices was highly heterogenous, the use of ACT or
327 other antimalarial by untested clients was uniformly high with much less variation between clusters (Fig
328 2).

329

330 The positivity rate of mRDTs conducted in the outlets was 13% as reported by customers exiting the
331 outlets, with no difference between the intervention and control arm. The low testing rate, combined

332 with a low positivity rate resulted in poor targeting of ACTs, with only 8.3% of all ACTs going to clients
 333 with confirmed malaria (Table 2, Table 3). Shops largely adhered to the recommended retail price for
 334 RDTs. Across arms, 85% (128/151) of clients confirmed they paid the RRP of 250 naira with only a small
 335 percentage paying more (5.3% or 8/151). Only a few clients that tested positive recalled what they paid
 336 for the ACT (28/56) and none of them reported receiving the ACT for free as intended by the
 337 intervention. Among those purchasing any ACTs, 50% reported paying >850 naira (263/527) with 29% of
 338 clients paying 650-850 naira (153/527). The mean price was 864 Naira with a median price of 700 Naira.
 339 No notable differences in ACT prices were observed across arms (Table 4).

340

341 **Table 4: Summary of price variables among ACT purchasers.**

Characteristics	Control, N = 558	Intervention, N = 626	Overall, N = 1,184
mRDT cost (Naira, categorized), n (%)			
0	0 (0%)	5 (5.8%)	5 (3.3%)
Don't know	3 (4.6%)	7 (8.1%)	10 (6.6%)
>250	4 (6.2%)	4 (4.7%)	8 (5.3%)
250	58 (89%)	70 (81%)	128 (85%)
Missing	493	540	1,033
ACT cost (Naira, categorized), n (%)			
0	0 (0%)	0 (0%)	0 (0%)
1-649	33 (13%)	32 (12%)	65 (12%)

Characteristics	Control, N = 558	Intervention, N = 626	Overall, N = 1,184
650-850	73 (29%)	80 (30%)	153 (29%)
>850	131 (51%)	132 (49%)	263 (50%)
Don't know	19 (7.4%)	27 (10.0%)	46 (8.7%)
Missing	302	355	657
ACT cost among test positive (Naira, categorized), n (%)			
0	0 (0%)	0 (0%)	0 (0%)
1-649	7 (39%)	1 (5.6%)	8 (22%)
650-850	2 (11%)	1 (5.6%)	3 (8.3%)
>850	7 (39%)	10 (56%)	17 (47%)
Don't know	2 (11%)	6 (33%)	8 (22%)
Missing	540	608	1,148
ACT cost among test negative/untested (Naira, categorized), n (%)			
1-649	26 (11%)	31 (12%)	57 (12%)
650-850	71 (30%)	79 (31%)	150 (31%)
>850	124 (52%)	122 (48%)	246 (50%)

Characteristics	Control, N = 558	Intervention, N = 626	Overall, N = 1,184
Don't know	17 (7.1%)	21 (8.3%)	38 (7.7%)
Missing	320	373	693
Why did you not pay anything for your ACT today?, n (%)			
Charged to insurance	0 (NA%)	0 (NA%)	0 (NA%)
Paid on credit	0 (NA%)	0 (NA%)	0 (NA%)
The ACT was offered for free at the outlet	0 (NA%)	0 (NA%)	0 (NA%)
Missing	558	626	1,184
Was there any discount for your ACT at the outlet today?, n (%)			
Yes	28 (11%)	29 (10%)	57 (11%)
No	124 (48%)	149 (54%)	273 (51%)
Don't know	106 (41%)	99 (36%)	205 (38%)
Missing	300	349	649

342

343 Clients testing positive reported spending a higher total amount at the outlet- a median of 1,425 Naira
 344 (n=56) vs. 950 Naira for those testing negative (n= 375) and 850 Naira for those not testing (n=1757),
 345 respectively (Table 5).

346

347 **Table 5: Total spent by test behavior and result.**

Characteristic	Positive, N = 56	Negative, N = 375	No mRDT, N = 1,757	Overall
How much did you spend at the pharmacy today? ('Don't know' as missing)				
Mean (SD)	1,534 (718)	1,078 (728)	1,026 (1,085)	1,048 (1,034)
Median [IQR]	1,425 [1,113, 2,000]	950 [550, 1,350]	850 [600, 1,200]	900 [600, 1,300]
Missing	2	77	107	186

348

349 Clients did not purchase injections in any significant proportion; 4.7% (6/127) of clients testing positive
 350 and 1.5% (25/1703) of clients untested. Just over a third (36%) of clients testing positive (20/56)
 351 purchased antibiotics; compared to 18% of those testing negative (66/375) and 29% (506/1,757) of
 352 untested clients (Table S3, Table S4).

353

354 Discussion

355 There have been several studies that have shown the feasibility introducing mRDTs in PMRs, including in
 356 Nigeria, with free or low cost mRDTs offered to clients, generally resulting in higher testing uptake
 357 among clients compared to a control arm or baseline survey [20, 21,22]. In our study, we provided low
 358 cost RDTs to both the intervention and control arms, with an additional financial incentive for PPMVs in

359 the intervention arm for each mRDT performed and reported through the study app, as well as a free
360 ACT for clients receiving a positive mRDT result.

361 PMRs in both arms largely adhered to the recommended RDT price. We found approximately 23% of
362 clients purchasing the mRDT. The additional incentive in the intervention arm, however, did not result in
363 any additional impact on testing.

364 Similarly, findings from other studies [23, 24, 25], show that introducing mRDTs in PMRs improved ACT
365 targeting with most clients procuring an ACT upon a positive result and a smaller proportion of clients
366 procuring an ACT or another antimalarial with a negative result. However, instructing the PMRs in the
367 intervention arm, to give the ACT for free to clients conditional on a positive result, like we did in our
368 study, did not have any additional impact on testing or targeting.

369 Study results in western Kenya, in which we implemented a similar trial, also found little impact of the
370 intervention on testing uptake or targeting of ACTs. Across both sites, we found testing uptake highly
371 heterogeneous among PMRs with many clients testing negative purchasing antimalarials and most
372 clients foregoing testing altogether while purchasing ACTs or other antimalarials. Clients testing positive
373 in both countries also spent more (and purchased more drugs) compared to untested patients or
374 patients testing negative. These results were found in both arms, with clients testing positive in the
375 intervention arm indicating they did not receive a discount or receive the ACT for free, as the
376 intervention intended.

377 There were, however, notable differences between the two study sites. In Kenya, we found a much
378 higher proportion of clients visiting the participating PMRs with malaria like symptoms compared to
379 Nigeria (i.e., eligible clients made up 51% of clients in Kenya, vs. 19% in Lagos and 82% of ineligible
380 clients in Lagos responded not experiencing malaria symptoms vs. 11% in Kenya). This higher proportion
381 was likely due to higher malaria prevalence in the Kenyan study site and may have contributed to the
382 much higher testing and positivity rate found in Kenya compared to Lagos (i.e., 49% and 35% compared

383 to 23% and 13% in Kenya and Nigeria, respectively). As a result, a much larger proportion of ACTs were
384 dispensed to clients testing positive in Kenya compared to Nigeria (27% vs. 8%, respectively). Clients
385 also purchased different types of drugs. In Kenya, a sizable proportion of clients testing positive
386 purchased injections (22%) instead of or in addition to an ACT compared to Nigeria (4.7%). Clients in
387 Kenya also were more likely to purchase ACT types other than AL compared to Nigeria.

388

389 The varying results between the two sites in testing uptake and treatment choice may reflect differences
390 in malaria prevalence, client preferences and their socio-economic status, or market conditions, among
391 other factors. Yet, the PMR-oriented financial incentive approach we took to increase RDT uptake and
392 lower the price of the ACTs to the client, conditional on the result of the mRDT, did not have an impact
393 on client or provider behavior in either setting. The shop attendants may not have understood or been
394 aware of the intervention, and profit incentives may have constrained behavior change, with shop
395 attendants charging for ACTs for RDT-positive clients in the intervention arm [26]. Suggestions from
396 participating PMRs following the study, solicited through group discussions, to increase test uptake and
397 adherence included further lowering the cost of the mRDT and ACT, building trust with clients around
398 the (negative) RDT result (i.e., clients often come in believing they have malaria) and alleviating concerns
399 that clients may see getting the test as an inconvenience. Results from a recent three arm randomized
400 control trial by Omale *et al* (2021) in Nigeria found that sensitizing caregivers through social group
401 meetings around the need for testing had a significant impact on testing uptake for under 5s in PPMVs,
402 with no significant difference between the social group arm and the arm that combined the social group
403 meetings with provider trainings [27], suggesting that educating clients and caregivers, promoting RDT
404 use, and advocating for adherence could further improve outcomes.

405 Efforts to increase use of RDTs in PMRs and adherence to test results should not only align with business
406 practices to make RDTs and ACTs available and affordable but include demand-side community

407 mobilization interventions, that could sensitize and empower patients to be sound decision makers
408 around malaria testing and drug choice.

409

410 *Conclusions*

411 Introduction of low cost RDTs to PMRs appears to improve targeting of ACTs among tested clients.
412 However, providing financial incentives to PMRs to increase testing uptake and adherence may not
413 result in additional improvements if the incentives are not well-understood or well-aligned with existing
414 business practices. In addition to interventions that can lower the out-of-pocket cost of RDTs and ACTs
415 for clients in PMRs, communities at risk should be sensitized to the benefits of testing in PMRs.

416

417 *Funding*

418 Research reported in this publication was supported by the National Institute Of Allergy And Infectious
419 Diseases of the National Institutes of Health under Award Number R01AI141444. The content is solely
420 the responsibility of the authors and does not necessarily represent the official views of the National
421 Institutes of Health. The funders had no role in study design, execution or analysis of the data.

422

423 *References*

424

- 425 1. World Health Organization. World Malaria Report 2023. Geneva; 2023. Available from:
426 <https://www.who.int/teams/global-malaria-programme/reports/world-malaria-report-2023>
- 427 2. World Health Organization. Report on malaria in Nigeria . Brazzaville; 2022. Available from:
428 <https://www.afro.who.int/countries/nigeria/publication/report-malaria-nigeria-2022-0>

- 429 3. National Malaria Elimination Programme (NMEP) [Nigeria] NPC (NPC) [Nigeria], and I. Nigeria
430 Malaria Indicator Survey 2021 . Abuja, Nigeria, and Rockville, Maryland, USA; 2022. Available
431 from: dhsprogram.com/pubs/pdf/MIS41/MIS41.pdf
- 432 4. Beyeler N, Liu J, Sieverding M. A systematic review of the role of proprietary and patent medicine
433 vendors in healthcare provision in Nigeria. *PLoS One*. 2015;10(1).
- 434 5. Oyeyemi AS, Ogunnowo BE, Odukoya OO. Patent medicine vendors in rural areas of Lagos
435 Nigeria: Compliance with regulatory guidelines and implications for malaria control. *Tropical*
436 *Journal of Pharmaceutical Research*. 2014;13(1).
- 437 6. Oladepo O, Oyeyemi AS, Titiloye MA, Adeyemi AO, Burnett SM, Apera I, et al. Malaria testing and
438 treatment knowledge among selected rural patent and proprietary medicine vendors (PPMV) in
439 Nigeria. *Malar J*. 2019;18(1).
- 440 7. Edwards HM, Sarwar R, Mahmud P, Emmanuel S, Maxwell K, Tibenderana JK. The private sector
441 market for malaria rapid diagnostic tests in Nigeria: results of the 2018 market survey. *Malar J*.
442 2022;21(1).
- 443 8. Laktabai J. A cluster-randomized trial of client and provider-directed financial interventions to
444 align incentives with appropriate case management in retail medicine outlets: results of the
445 TESTsmART Trial in western Kenya. *Medrxiv*. 2023; Available from:
446 <https://pubmed.ncbi.nlm.nih.gov/37745516/>
- 447 9. Woolsey AM, Simmons RA, Woldeghebriel M, Zhou Y, Ogunsola O, Laing S, et al. Incentivizing
448 appropriate malaria case management in the private sector: a study protocol for two linked
449 cluster randomized controlled trials to evaluate provider- and client-focused interventions in
450 western Kenya and Lagos, Nigeria. *Implementation Science*. 2021;16(1).
- 451 10. Woolsey AM, Simmons RA, Woldeghebriel M, Zhou Y, Ogunsola O, Laing S, et al. Correction to:
452 Incentivizing appropriate malaria case management in the private sector: a study protocol for

- 453 two linked cluster randomized controlled trials to evaluate provider- and client-focused
454 interventions in western Kenya and Lagos, Nigeria (Implementation Science, (2021), 16, 1, (14),
455 10.1186/s13012-020-01077-w). Vol. 16, Implementation Science. 2021.
- 456 11. Federal Ministry of Health. National Policy on Malaria Diagnosis and Treatment. Abuja; 2011.
457 Available from: <https://pipnigeria.ebsu.edu.ng/malariapolicy.php>
- 458 12. Hayes RJ, Moulton LH. Cluster randomised trials, second edition. Cluster Randomised Trials,
459 Second Edition. 2017.
- 460 13. Hemming K, Kasza J, Hooper R, Forbes A, Taljaard M. A tutorial on sample size calculation for
461 multiple-period cluster randomized parallel, cross-over and stepped-wedge trials using the shiny
462 CRT calculator. Int J Epidemiol. 2020;49(3).
- 463 14. Zou G. A Modified Poisson Regression Approach to Prospective Studies with Binary Data. Am J
464 Epidemiol. 2004;159(7).
- 465 15. Zou GY, Donner A. Extension of the modified Poisson regression model to prospective studies
466 with correlated binary data. Stat Methods Med Res. 2013;22(6).
- 467 16. Pepe MS, Anderson GL. A cautionary note on inference for marginal regression models with
468 longitudinal data and general correlated response data. Commun Stat Simul Comput. 1994;23(4).
- 469 17. Kauermann G, Carroll RJ. A note on the efficiency of sandwich covariance matrix estimation. J Am
470 Stat Assoc. 2001;96(456).
- 471 18. Li P, Redden DT. Small sample performance of bias-corrected sandwich estimators for cluster-
472 randomized trials with binary outcomes. Stat Med. 2015;34(2).
- 473 19. Preisser JS, Lu B, Qaqish BF. Finite sample adjustments in estimating equations and covariance
474 estimators for intracluster correlations. Stat Med. 2008;27(27).
- 475 20. Goodman C, Tougher S, Shang TJ, Visser T. Improving malaria case management with artemisinin-
476 based combination therapies and malaria rapid diagnostic tests in private medicine retail outlets

- 477 in sub-Saharan Africa: a systematic review. *J Public Health Afr.* 2023; Available from:
478 <https://www.medrxiv.org/content/10.1101/2023.05.23.23290407v1>
- 479 21. Visser T, Bruxvoort K, Maloney K, Leslie T, Barat LM, Allan R, et al. Introducing malaria rapid
480 diagnostic tests in private medicine retail outlets: A systematic literature review. Vol. 12, *PLoS*
481 *ONE.* 2017.
- 482 22. Leurent B, Bruxvoort K, Grieve E, Hutchinson E, Reynolds J, Leslie T. Impact of malaria rapid
483 diagnostic tests on care of febrile patients: Cross-project results from the act consortium.
484 *American Journal of Tropical Medicine and Hygiene.* 2014;Conference.
- 485 23. Mbonye AK, Magnussen P, Lal S, Hansen KS, Cundill B, Chandler C, et al. A cluster randomised
486 trial introducing rapid diagnostic tests into registered drug shops in Uganda: Impact on
487 appropriate treatment of malaria. *PLoS One.* 2015;10(7).
- 488 24. Ansah EK, Narh-Bana S, Affran-Bonful H, Bart-Plange C, Cundill B, Gyapong M, et al. The impact of
489 providing rapid diagnostic malaria tests on fever management in the private retail sector in
490 Ghana: A cluster randomized trial. *BMJ (Online).* 2015;350.
- 491 25. Maloney K, Ward A, Krenz B, Petty N, Bryson L, Dolkart C, et al. Expanding access to parasite-
492 based malaria diagnosis through retail drug shops in Tanzania: evidence from a randomized trial
493 and implications for treatment. *Malar J.* 2017;16(1).
- 494 26. Wafula FN, Goodman CA. Are interventions for improving the quality of services provided by
495 specialized drug shops effective in sub-Saharan Africa? A systematic review of the literature. Vol.
496 22, *International Journal for Quality in Health Care.* 2010.
- 497 27. Omale UI, Azuogu BN, Alo C, Madubueze UC, Oka OU, Okeke KC, et al. Social group and health-
498 care provider interventions to increase the demand for malaria rapid diagnostic tests among
499 community members in Ebonyi state, Nigeria: a cluster-randomised controlled trial. *Lancet Glob*
500 *Health.* 2021;9(3).


Figures

Figure 1: Flow diagram of shop enrollment, randomization and client interviews

Figure 2: ACT and RDT uptake by outlet


Figure 1: Flow diagram of shop enrollment, randomization and client interviews

medRxiv preprint doi: <https://doi.org/10.1101/2024.01.30.24302026>; this version posted February 1, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).



- a. Exclusion criteria are not mutually exclusive, so sum of specific reasons may exceed total number ineligible
 b. "other" reasons for exclusion were: patient younger than 1 year of age; and patient had symptoms of severe malaria and referred for care.

Figure 2: ACT and RDT uptake by outlet*.



* Outlets are grouped in columns by arm and ordered by proportion tested from highest (top) to lowest (bottom). Each outlet block is divided vertically to illustrate the proportion with positive mRDT, negative mRDT, and no mRDT. Each test result section of each block is divided horizontally to illustrate the ACT purchasing behavior among those participant